Search the Newsreel

Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday

Inovio Pharmaceuticals (NASDAQ: INO) is expected to announce its Q2 2026 earnings on Wednesday, August 12th, with analysts forecasting a loss of $0.25 per share and revenue of $0.533 million. The company's stock opened at $0.66, near its 52-week low, and institutional investors have …

Viohalco S A : H1 2026 Financial Results

Viohalco SA/NV Revenue Breakdown – ATHEX:VIO

Navios Maritime Partners L.P. (NMM) CEO in 10b5-1 unit buys

Entities affiliated with Angeliki Frangou, CEO and Chairwoman of Navios Maritime Partners L.P. (NMM), purchased a total of 2,524 common units in indirect transactions on July 31, August 3, and August 4, 2026. These purchases were made under a Rule 10b5-1 trading plan at …

Cheviot net profit surges 58% in Q1FY27 on strong revenue growth

Cheviot Company standalone net profit rises 57.75% in the June 2026 quarter

Cheviot Standalone Net Profit Rises To ₹45.3 Crore Versus ₹28.7 Crore YoY

Cheviot Company Ltd Returns to Profitability with ₹45.29 Crore Net Profit in June 2026 Quarter

INOVIO to Report Second Quarter Financial Results on August 12, 2026

INOVIO (NASDAQ: INO) announced it will release its second-quarter 2026 financial results after the market close on August 12, 2026. Following the release, the biotechnology company will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide …

Navios Maritime Partners (NYSE:NMM) Insider Acquires 1,041 Shares of Stock

Navios Maritime Partners (NYSE:NMM) insider Angeliki Frangou recently acquired 1,041 shares of the company's stock for $82,176.54, increasing her total holdings to 4.78 million shares. This purchase is part of a series of acquisitions made since July 20th, highlighting continued insider buying. The company …

Artivion (AORT) To Report Earnings Tomorrow: Here Is What To Expect

red violet expects $100M raise for working capital, potential strategic acquisitions

Red Violet, Inc. (NASDAQ: RDVT) announced the pricing of an underwritten public offering of 1,666,667 common shares at $60.00 per share, aiming to raise $100 million in gross proceeds. The company plans to use the net proceeds for working capital, general corporate purposes, and …

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Inovio Pharmaceuticals Inc. (INO) shares fell 4.84% to $0.66 on Tuesday, despite an overall positive trading session for the stock market. The NASDAQ Composite Index and the Dow Jones Industrial Average both saw significant gains. This decline broke a two-day winning streak for Inovio's …

INOVIO's Aug. 12 Results Call Includes Live Analyst Q&A

INOVIO (NASDAQ: INO) announced it will release its second quarter 2026 financial results after market close on August 12, 2026. The company will host a live, listen-only conference call and webcast at 4:30 p.m. ET on the same day to discuss the results and …

Indivior Pharmaceuticals, Inc. Quarterly Earnings Report

Indivior Pharmaceuticals, Inc. (INDV) has released its Q2 2026 earnings report, detailing an increase in net revenue driven by strong U.S. sales of SUBLOCADE. The company also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc., which includes a conditional $1 billion special cash …

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential

Indivior Pharmaceuticals, Inc. (INDV) is positioned as a key player in opioid dependence treatment, with strong analyst consensus pointing to a 36% upside potential. The company's focus on buprenorphine-based treatments, robust revenue growth of 19.20%, and a product pipeline including SUBLOCADE and SUBOXONE contribute …

$1.8bn merger unites Supernus and Indivior in CNS therapeutics play

Supernus Pharmaceuticals and Indivior Pharmaceutical are merging in an all-stock transaction valued at $1.8 billion, aiming to create a stronger entity in the CNS therapeutics space. The combined company, to be named Supernus, Inc., will leverage commercial and pipeline synergies across neurological and psychiatric …

Is Artivion (AORT) Undervalued As Investors Reassess Its Growth And Capital Efficiency?

Artivion (AORT) is being re-evaluated by investors due to its smaller revenue base, limited free cash flow, and capital efficiency challenges. Despite a 14.6% share price increase over the last month, the company has seen a 20.9% decline over 90 days. While some narratives …

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

indivior plc. Positive Earnings Pre-Announcements

Indivior plc. (INDV.L, INDV) has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance upwards from an estimated range of $1.215 - $1.285 Billion to $1.295 - $1.365 Billion. This announcement is part of a broader calendar of earnings pre-announcements available through RTTNews. …

Viohalco (ENXTBR:VIO) Reports Stronger Half Year Results, Is The Premium Valuation Justified?

Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Cuts Target Price to $4

Piper Sandler has reiterated its Buy rating on Inovio Pharmaceuticals (INO.US) but has lowered its price target for the stock to $4. This adjustment reflects an updated valuation for the company.

Supernus, Indivior merge to beef up brain drug portfolio

Brain drug developers Supernus and Indivior have announced a merger aimed at combining their portfolios of neurological drugs. The new entity, to be called Supernus, will have a combined revenue of $2 billion (2025 figures) and aims to achieve annual cost reductions of $125 …

Indivior Shares Surge After Strong Quarterly Results and Higher 2026 Outlook

Stock chart with red arrow going up ©Pixabay Indivior Pharmaceuticals Inc. (NASDAQ:INDV) reported better-than-expected second-quarter 2026 results on Monday, driven by record sales of its opioid use disorder treatment SUBLOCADE, while raising its full-year financial guidance. The stronger outlook sent the pharmaceutical company's shares …

Indivior stock soars 9% on strong earnings beat and raised guidance

Indivior Pharmaceuticals Inc. (NASDAQ:INDV) saw its stock rise by 9.22% after reporting strong second-quarter results that exceeded analyst expectations. The company also raised its full-year 2026 revenue and adjusted EBITDA guidance, driven by record SUBLOCADE net revenue. This performance reflects strong operational execution and …

Supernus and Indivior Combine to Build $2.2B CNS Biopharmaceutical Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a $2.2 billion central nervous system (CNS) biopharmaceutical company. The combined entity, operating as Supernus, Inc., will integrate Indivior's opioid use disorder franchise, centered on SUBLOCADE, with Supernus's diverse neurology and …

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

Indivior Pharmaceuticals reported strong second-quarter 2026 financial results, with total net revenue up 14% year-over-year to $343 million and SUBLOCADE net revenue increasing by 21% to $253 million. The company has raised its full-year 2026 guidance, now expecting total SUBLOCADE net revenue growth of …

Inovio Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:INO)

Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates

Form 4 Indivior PLC For: 3 August By Investing.com

This article announces the filing of Form 4 for Indivior PLC on August 3rd. It appears to be a very brief notification from Investing.com, typical of automated financial news updates regarding regulatory filings. The content primarily consists of navigation, advertisements, and market data rather …

Understanding Momentum Shifts in (RDVT)

This article analyzes Red Violet Inc. (RDVT) using AI models, indicating strong near-term sentiment but a neutral mid and long-term outlook. It highlights compelling upside potential due to the absence of resistance levels above the current price and provides specific trading strategies for different …

Indivior PLC (NASDAQ:INDV) Given Average Recommendation of "Moderate Buy" by Brokerages

Indivior PLC (NASDAQ:INDV) has received an average "Moderate Buy" recommendation from seven brokerages, with an average 12-month price target of $43.67. The company's stock opened at $40.01, and analysts project full-year earnings of $4.05 per share. Recent insider transactions show executives selling shares under …

Artivion, Inc. Revenue Breakdown – HAM:CYL

Artivion, Inc. (CYL) generated 375.76 million EUR in revenue last year. Its Medical Devices segment was the top performer, contributing 294.44 million EUR. The United States was the primary regional contributor, accounting for 182.27 million EUR of the total revenue.

Indivior Q2 2026 slides: SUBLOCADE drives 111% EBITDA surge

Indivior PLC reported strong Q2 2026 financial results, with adjusted EBITDA surging 111% driven by its opioid use disorder treatment, SUBLOCADE. Despite exceeding analyst expectations, the company's stock experienced a slight decline, likely due to investor caution regarding its proposed merger with Supernus Pharmaceuticals. …

Indivior Q2 Earnings Call Highlights

Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, expected to close in Q4 2026, creating a CNS-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus …

Inovio proposes underwritten public offering of common stock, warrants

Inovio has initiated an underwritten public offering of common stock and accompanying warrants, or pre-funded warrants in lieu of common stock. Piper Sandler is the sole manager for this offering, which includes a 30-day option for underwriters to purchase up to an additional 15% …